Mylan Inc. (MYL) Given a $52.00 Price Target at JPMorgan Chase & Co.
MYL has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Mylan from a hold rating to a buy rating and set a $49.00 target price on the stock in a report on Tuesday, July 5th. Leerink Swann set a $45.00 target price on shares of Mylan and gave the company a buy rating in a report on Saturday. TheStreet upgraded shares of Mylan from a hold rating to a buy rating in a report on Friday, August 12th. BTIG Research restated a buy rating and set a $60.00 target price on shares of Mylan in a report on Tuesday, August 30th. Finally, RBC Capital Markets dropped their target price on shares of Mylan from $52.00 to $48.00 and set a sector perform rating on the stock in a report on Tuesday, September 6th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $53.58.
Mylan (NASDAQ:MYL) remained flat at $37.97 during mid-day trading on Tuesday. The stock had a trading volume of 3,776,463 shares. The firm has a market cap of $20.31 billion, a P/E ratio of 24.03 and a beta of 1.14. Mylan has a 52 week low of $37.41 and a 52 week high of $55.51. The company has a 50 day moving average of $42.30 and a 200-day moving average of $44.35.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Tuesday, August 9th. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.03. The business had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Mylan had a net margin of 8.11% and a return on equity of 23.22%. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.91 earnings per share. On average, analysts forecast that Mylan will post $4.96 EPS for the current fiscal year.
In related news, CEO Heather M. Bresch sold 100,200 shares of the stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $50.00, for a total value of $5,010,000.00. Following the completion of the sale, the chief executive officer now directly owns 828,318 shares of the company’s stock, valued at approximately $41,415,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.71% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC raised its stake in Mylan by 43.6% in the second quarter. Advisory Services Network LLC now owns 2,537 shares of the company’s stock valued at $110,000 after buying an additional 770 shares in the last quarter. Checchi Capital Advisers LLC raised its stake in Mylan by 6.6% in the second quarter. Checchi Capital Advisers LLC now owns 2,637 shares of the company’s stock valued at $114,000 after buying an additional 164 shares in the last quarter. Integrated Investment Consultants LLC purchased a new stake in Mylan during the second quarter valued at about $145,000. Tower Research Capital LLC TRC raised its stake in Mylan by 100.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,182 shares of the company’s stock valued at $181,000 after buying an additional 2,095 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Mylan by 48.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,235 shares of the company’s stock valued at $184,000 after buying an additional 1,388 shares in the last quarter. 60.20% of the stock is owned by institutional investors.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc. and related stocks with our FREE daily email newsletter.